Alvogen nabs four Pfizer products; Brazil's pharma market to approach $48B by 2020: report;

> Alvogen has acquired a portfolio of four pharma products from Pfizer ($PFE). Release

> Brazil's pharma market will near $48 billion by 2020, GlobalData says. Release

> Amneal has created a new biosciences unit that will focus on injectables, oncologics, biosimilars and other products that have high barriers to entry. Release

> Mylan ($MYL) has launched a generic of Pfizer's anti-infective combo Zosyn. Release

> British health secretary Jeremy Hunt is to create tough new rules designed to criminalize some gifts and financial payments between doctors and pharma companies. Report

Suggested Articles

Alexion and Amgen reached a deal to put off a biosimilar challenger to Alexion's blockbuster rare disease med Soliris until March 2025.

AZ's tremelimumab has so far suffered a host of clinical failures. But new trial results show the company might be able to use the drug in a new way.

Roche may have just grabbed the first FDA nod for a checkpoint med in previously untreated liver cancer, but Merck is hoping it won’t be far behind.